Agios Pharmaceuticals AGIO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's EPS (diluted)?
- Agios Pharmaceuticals (AGIO) reported EPS (diluted) of -$1.69 in Q1 2026.
- How has Agios Pharmaceuticals's EPS (diluted) changed year-over-year?
- Agios Pharmaceuticals's EPS (diluted) decreased by 9.0% year-over-year, from -$1.55 to -$1.69.
- What is the long-term trend for Agios Pharmaceuticals's EPS (diluted)?
- Over 2 years (2021 to 2025), Agios Pharmaceuticals's EPS (diluted) has grown at a -43.5% compound annual growth rate (CAGR), from $22.24 to -$7.11.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.